Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3699671 | 0.93 | NAMPT (1.00) | NAMPT | |
| SCHEMBL3707618 | 0.85 | NAMPT (0.86) | NAMPTSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL3707279 | 0.85 | NAMPT (1.00) | NAMPTMEN1KMT2A | |
| SCHEMBL3702488 | 0.84 | NAMPT (1.00) | NAMPT | |
| SCHEMBL3708985 | 0.84 | NAMPT (0.88) | NAMPTSMN1; SMN2RAB9ANPC1MAPK1 | |
| SCHEMBL3698767 | 0.81 | RAB9A (0.79) | NAMPTSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL3697722 | 0.81 | NAMPT (1.00) | NAMPT | |
| SCHEMBL4283175 | 0.79 | NAMPT (0.69) | NAMPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3703136 | 0.79 | NAMPT (0.69) | NAMPTSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL3708603 | 0.78 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885SMN1; SMN2 334/4885RAB9A 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.